Achieve over 98% viability and up to a 10% recovery increase in automated leukapheresis cryopreservation

Comparative process data show that IntegriCell^®, an automated closed cryopreservation platform, standardises leukapheresis starting material quality and improves recovery across global CGT manufacturing supply chains.

In our interactive summary and video, Alice Bouchoms (Cryoport Systems | IntegriCell) shows you how you can achieve:

✓

>98% average cell viability before freezing, consistent across US and EU processing sites

✓

~95% average cell viability after thawing, with no significant site-to-site differences

✓

5–10% increase in cell recovery through data-driven process optimisation

✓

Maintained wash efficiency, with comparable red blood cell and platelet removal post-optimisation

▶

Click image above to see a taster video

Want to learn more?

View the interactive summary and video for free by clicking the link below.

✕

Please enter your email to access content Read now